Repligen (NASDAQ:RGEN) Earns Buy Rating from Analysts at Roth Mkm

Equities research analysts at Roth Mkm initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Friday,Benzinga reports. The brokerage set a “buy” rating and a $160.00 price target on the biotechnology company’s stock. Roth Mkm’s price target would indicate a potential upside of 20.16% from the company’s current price.

Several other research firms have also recently issued reports on RGEN. Wells Fargo & Company lowered their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $172.36.

Repligen Price Performance

RGEN stock traded up $6.07 during trading on Friday, hitting $133.16. The stock had a trading volume of 101,425 shares, compared to its average volume of 811,898. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. Repligen has a twelve month low of $109.66 and a twelve month high of $175.77. The stock has a market capitalization of $7.51 billion, a P/E ratio of 156.76, a PEG ratio of 2.58 and a beta of 1.19. The company’s 50-day moving average price is $124.86 and its two-hundred day moving average price is $146.25.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. During the same period in the previous year, the firm posted $0.44 EPS. Repligen’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in the company. Bayforest Capital Ltd purchased a new stake in Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen in the fourth quarter valued at approximately $33,000. Measured Wealth Private Client Group LLC purchased a new stake in Repligen in the third quarter valued at approximately $29,000. Los Angeles Capital Management LLC purchased a new stake in Repligen in the fourth quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC raised its position in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.